2026-07-13 Eisai Co.,Ltd. “Clinical data supporting the efficacy and safety of the "Rekenbi®" subcutaneous autoinjector, comparable to intravenous formulations, in early Alzheimer's disease were presented at AAIC 2026. New clinical and real-world data support a subcutaneous treatment pathway from initial therapy to ongoing therapy, contributing to improved convenience for patients and care partners.”